Lenzilumab

From WikiMD.org
Jump to navigation Jump to search

Lenzilumab

Lenzilumab (pronounced len-zil-yoo-mab) is a monoclonal antibody designed for the treatment of various diseases. It is currently being studied for its potential use in the treatment of COVID-19 and other conditions.

Etymology

The name "Lenzilumab" is derived from the combination of the prefix "Lenzi-", which is a proprietary designation by the drug's developer, Humanigen, and "-lumab", a suffix used in the International Nonproprietary Names (INN) for monoclonal antibodies.

Usage

Lenzilumab is currently being investigated for its potential use in treating patients with COVID-19. It is designed to target and neutralize granulocyte-macrophage colony-stimulating factor (GM-CSF), a critical cytokine that drives the hyperinflammatory immune response associated with COVID-19.

Related Terms

  • Monoclonal Antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells.
  • COVID-19: An infectious disease caused by a newly discovered coronavirus.
  • Cytokine: A type of protein that plays an important role in cell signaling.
  • GM-CSF: A protein secreted by certain immune cells that stimulates the production of other immune cells.

See Also

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski